One of the two N-glycans on the human Gb3/CD77 synthase is essential for its activity and allosterically regulates its function.

Gb3/CD77 synthase Glycosyltransferase HEK293 N-glycan P1PK blood group Protein modeling

Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
20 08 2022
Historique:
received: 05 05 2022
revised: 17 05 2022
accepted: 27 05 2022
pubmed: 8 6 2022
medline: 22 6 2022
entrez: 7 6 2022
Statut: ppublish

Résumé

N-glycosylation is a posttranslational modification that influences many protein properties, such as bioactivity, folding or solubility. The same principles apply to key enzymes in glycosylation pathways, including glycosyltransferases, that also undergoing N-glycosylation, changes in which may affect their activity. Human Gb3/CD77 synthase (encoded by A4GALT) is a Golgi-resident glycosyltransferase, which catalyzes the synthesis of Galα1→4Gal disaccharide on glycosphingolipid- and glycoprotein-derived acceptors, creating Gb3 or P1 antigens and P1 glycotopes (Galα1→4Galβ1→4GlcNAc-R), respectively. The molecules that contain Galα1→4Gal serve as receptors for pathogens and Shiga toxins, which are the major virulence factors of Shiga toxin-producing Escherichia coli (STEC). Human Gb3/CD77 synthase contains two N-glycosylation sites at positions N

Identifiants

pubmed: 35671609
pii: S0006-291X(22)00802-6
doi: 10.1016/j.bbrc.2022.05.085
pii:
doi:

Substances chimiques

Glycosphingolipids 0
Polysaccharides 0
Galactosyltransferases EC 2.4.1.-
UDP-galactose-lactosylceramide alpha 1-4-galactosyltransferase EC 2.4.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-41

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Krzysztof Mikolajczyk (K)

Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114, Wroclaw, Poland. Electronic address: krzysztof.mikolajczyk@hirszfeld.pl.

Mateusz Sikora (M)

Department of Theoretical Biophysics, Max Planck Institute for Biophysics, 60438 Frankfurt Am Main, Germany; Faculty of Physics, University of Vienna, 1090, Vienna, Austria.

Cyril Hanus (C)

Institute of Psychiatry and Neurosciences of Paris, Inserm UMR1266 - Université Paris Cité, Paris, France.

Radoslaw Kaczmarek (R)

Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114, Wroclaw, Poland.

Marcin Czerwinski (M)

Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114, Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH